Tag Archives: Larger

Akebia crashes on vadadustat flop in larger anemia indication. Will AZ, FibroGen own the market?

What was previously expected to be a three-way battle in the novel HIF-PHI renal anemia drug class now has one man down. Akebia Therapeutics has posted a surprise trial flop, which one analyst said could hand the rival FibroGen-AstraZeneca team an early monopoly of the market. On Thursday, Akebia said its Otsuka-partnered vadadustat was linked to… Read More »

As NYC declares emergency over measles outbreak in small area, larger city is threatened

A measles outbreak among a small segment of schoolchildren in New York has prompted the city’s Mayor Bill de Blasio to declare the public health crisis an emergency in parts of Brooklyn. But the actual danger is the sheer number of children in the the NYC public school system that go unvaccinated — which threatens… Read More »